Effect of Benralizumab in Atopic Dermatitis
Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.
Sponsor: AstraZeneca
Listed as NCT03563066, this PHASE2 trial focuses on Dermatitis and Dermatitis, Atopic and remains completed. Sponsored by AstraZeneca, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Nov 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- McMaster University
For direct contact, visit the study record on ClinicalTrials.gov .